Cirrhosis Website Links For
Cirrhosis 		 

Information About

Cirrhosis
  CATEGORIES ABOUT CIRRHOSIS
   
gastroenterology
   
hepatology
   
alcohol abuse
   
SHOPPER'S DELIGHT
 
Shop For:  
Department
Price Minimum:
Price Maximum:
      



  ICD10 K70, K71, K74
  ICD9


Cirrhosis is a consequence of chronic liver disease characterized by replacement of liver tissue by fibrotic scar tissue as well as regenerative nodules, leading to progressive loss of liver function. Cirrhosis is most commonly caused by alcoholism and hepatitis C, and was the 12th leading cause of death in the United States in 2000.Anderson RN. "Deaths: leading causes for 2000" National vital statistics reports. 2003;50:16 PMID 16485447 Ascites is the most common complication of cirrhosis and is associated with a poor quality of life, increased risk of infections, and a poor long term outcome. In advanced stages of cirrhosis, the condition is irreversible and the only option would be a liver transplant.


SYMPTOMS AND SIGNS

The following signs and symptoms may occur in the presence of cirrhosis or as a result of the complications of cirrhosis. Many are nonspecific and may occur in other diseases and does not necessarily point to cirrhosis. Likewise, the absence of any does not rule out the possibility of cirrhosis.



Complications

As the disease progresses, complications may develop. In some people, these may be the first signs of the disease.


CAUSES

Cirrhosis has many possible causes; sometimes more than one cause are present in the same patient. In the Western World, chronic alcoholism and hepatitis C are the most common causes.














DIAGNOSIS

The gold standard for diagnosis of cirrhosis is a liver biopsy, through a percutaneous, transjugular, laparoscopic, or fine-needle approach. Histologically cirrhosis can be classified as micronodular, macronodular, or mixed, but this classification has been abandoned since it is nonspecific to the etiology, it may change as the disease progresses, and serological markers are much more specific. However, a biopsy is not necessary if the clinical, laboratory, and radiologic data suggests cirrhosis.


Lab findings




Imaging

Ultrasound is routinely used in the evaluation of cirrhosis, where it may show a small and nodular liver in advanced cirrhosis along with increased echogenicity with irregular appearing areas. Ultrasound may also screen for hepatocellular carcinoma and portal hypertension. Other tests --- which are not routinely used --- include the "stiffness" measurement, CT, MRI, and nuclear studies.


PATHOLOGY

Macroscopically, the liver may be initially enlarged, but with progression of the disease, it becomes smaller. Its surface is irregular, the consistency is firm and the color is often yellow (if associates 's cirrhosis or portal cirrhosis) regenerating nodules are under 3 mm. In macronodular cirrhosis (post-necrotic cirrhosis), the nodules are larger than 3 mm. The mixed cirrhosis consists in a variety of nodules with different sizes.
Microscopically, cirrhosis is characterized by regeneration nodules, surrounded by fibrous septa. In these nodules, regenerating hepatocytes are disorderly disposed. Portal tracts, central veins and the radial pattern of hepatocytes are absent. Fibrous septa are important and may present inflammatory infiltrate (lymphocytes, macrophages) If it is a secondary biliary cirrhosis, biliary ducts are damaged, proliferated or distended - bile stasis. These dilated ducts contain inspissated bile which appear as bile casts or bile thrombi (brown-green, amorphous). Bile retention may be found also in the parenchyma, as the so called "bile lakes". 1


PATHOPHYSIOLOGY

The liver plays a vital role in synthesis of proteins (e.g. Albumin , Clotting Factors and Complement ), detoxification and storage (e.g. Vitamin A ). In addition, it participates in the metabolism of Lipid s and Carbohydrate s.

Cirrhosis is often preceded by hepatitis and fatty liver (steatosis), independent of the cause. If the cause is removed at this stage, the changes are still fully reversible.

The pathological hallmark of cirrhosis is the development of scar tissue that replaces normal Parenchyma , blocking the portal flow of blood through the organ and disturbing normal function. Iredale (2003) summarises the pivotal role of Stellate Cell , a cell type that normally stores Vitamin A , in the development of cirrhosis. Damage to the hepatic parenchyma leads to activation of the stellate cell, which becomes contractile and obstructs blood flow in the circulation. In addition, it secretes TGF-β1 , which leads to a fibrotic response and proliferation of Connective Tissue . Furthermore, it disturbs the balance between Matrix Metalloproteinase s and the naturally occurring inhibitors (TIMP 1 and 2), leading to Matrix breakdown and replacement by connective tissue-secreted matrix.

The fibrous tissue bands (septa) separate hepatocyte nodules, which eventually replace the entire liver architecture, leading to decreased blood flow throughout. The Spleen becomes congested, which leads to Hypersplenism and increased sequestration of Platelet s. Portal hypertension is responsible for most severe complications of cirrhosis.


TREATMENT

Liver damage from cirrhosis cannot be reversed, but treatment can stop or delay further progression and reduce complications. Close follow-up is often necessary. Alcohol and Acetaminophen , as well as other potentially damaging substances, are discouraged. A healthy diet is encouraged, as cirrhosis may be an energy-consuming process. Salt restriction is often necessary, as cirrhosis leads to accumulation of salt (sodium retention). High-protein food increases the Nitrogen Balance , and would theoretically increase Encephalopathy ; in the past, this was therefore eliminated as much as possible from the diet. Recent studies show that this assumption was incorrect, and high-protein foods are even ''encouraged'' to maintain adequate nutrition.

Treatment exists of elimination of the causes and preventing complications:

In severe complications from portal hypertension, Transjugular Intrahepatic Portosystemic Shunt ing is occasionally indicated to relieve pressure on the portal vein.

If complications cannot be controlled or when the liver ceases functioning, a Liver Transplant is necessary. Survival from liver transplantation has been improving over the 1990s and is now around 90%, depending largely on the severity of disease in the recipient. Transplantation necessitates the use of immune suppressants ( Cyclosporine or Tacrolimus ).


REFERENCES